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BACKGROUND: Treatment decisions for patients with early-stage breast cancer often involve discussions with multiple oncology 
providers. However, the extent to which primary care providers (PCPs) are involved in initial treatment decisions remains 
unknown. METHODS: A stratified random sample of PCPs identified by newly diagnosed patients with early-stage breast cancer 
from the Georgia and Los Angeles Surveillance, Epidemiology, and End Results registries were surveyed (n = 517; a 61% response 
rate). PCPs were asked how frequently they discussed surgery, radiation, and chemotherapy options with patients; how comfort-
able they were with these discussions; whether they had the necessary knowledge to participate in decision making; and what 
their confidence was in their ability to help (on 5-item Likert-type scales). Multivariate logistic regression was used to identify 
PCP-reported attitudes associated with more PCP participation in each treatment decision. RESULTS: In this sample, 34% of PCPs 
reported that they discussed surgery, 23% discussed radiation, and 22% discussed chemotherapy options with their patients. Of 
those who reported more involvement in surgical decisions, 22% reported that they were not comfortable having a discussion, 
and 17% did not feel that they had the necessary knowledge to participate in treatment decision making. PCPs who positively 
appraised their ability to participate were more likely to participate in all 3 decisions (odds ratio [OR] for surgery, 6.01; 95% con-
fidence interval [CI], 4.16-8.68; OR for radiation, 8.37; 95% CI, 5.16-13.58; OR for chemotherapy, 6.56; 95% CI, 4.23-10.17). 
CONCLUSIONS: A third of PCPs reported participating in breast cancer treatment decisions, yet gaps in their knowledge about 
decision making and in their confidence in their ability to help exist. Efforts to increase PCPs’ knowledge about breast cancer 
treatment options may be warranted. Cancer 2019;125:1815-1822. © 2019 American Cancer Society. 
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INTRODUCTION
Women diagnosed with early-stage breast cancer are faced with multiple complex treatment decisions. During this 
treatment decision-making process, they often discuss their treatment options with a number of cancer physicians as 
well as family and friends.1-8 Patients may also increasingly consult their primary care providers (PCPs) about treatment 
decisions, particularly as the cancer population ages9 and collaborative care models10,11 are adopted in practice. Prior 
studies suggest that PCP involvement in collaborative cancer care often begins as early as diagnosis, and they support 
the idea that many PCPs remain engaged during the acute treatment phase.12,13 In addition, population-based surveys of 
patients with early-stage cancer suggest that patients perceive their PCPs to be participating in their treatment decisions, 
with approximately one-third of patients with breast cancer reporting that their PCP participated in their treatment 
decisions.12 Yet, we know little about the extent to which PCPs perceive that they are participating in multimodal treat-
ment decisions, and how they appraise their ability to effectively participate in shared decision making in this context 
remains unclear.
Corresponding author: Lauren P. Wallner, PhD, MPH, University of Michigan, 2800 Plymouth Road, Building 16-409E, Ann Arbor, MI 48109; lwallner@med.umich.edu
1 Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; 2 Department of Epidemiology, University of Michigan, Ann Arbor, Michigan; 
3 Department of Biostatistics, University of Michigan, Ann Arbor, Michigan; 4 Department of Medicine, Stanford University, Stanford, California; 5 Department of 
Health Research and Policy, Stanford University, Stanford, California; 6 Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; 7 Center 
for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, Michigan; 8 Department of Preventive Medicine, University of Southern California 
Keck School of Medicine, Los Angeles, California; 9 Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia; 10 Department of 
Health Management and Policy, University of Michigan, School of Public Health, Ann Arbor, Michigan; 11 Department of Health Behavior and Education, University of 
Michigan, School of Public Health, Ann Arbor, Michigan.
The last 2 authors contributed equally to this article.
Additional Supporting Information may be found in the online version of this article. 
DOI: 10.1002/cncr.31998, Received: November 9, 2018; Revised: December 14, 2018; Accepted: December 24, 2018, Published online February 1, 2019 in Wiley 
Online Library  (wileyonlinelibrary.com)
Original Article
1816 Cancer  June 1, 2019
Therefore, the goals of this study were to  evaluate to 
what extent PCPs report that they participate in surgical, 
radiation, and chemotherapy decisions for early-stage 
breast cancer and to characterize PCPs’ perspectives on 
their ability to participate in these decisions. We also 
examined whether PCPs’ appraisal of their ability to 
participate in these decisions was associated with their 
participation in treatment decision making. Finally, 
we explored whether the PCP-reported level of involve-
ment in the 3 treatment decisions was concordant with 
patients’ reports of their PCPs’ involvement in their 
treatment decisions.
MATERIALS AND METHODS
Study Population
The Individualized Cancer Care (iCanCare) study 
is a large, population-based survey study of women 
with early-stage breast cancer and their providers; it 
has been described previously.14-16 We identified and 
accrued women aged 20 to 79 years with newly 
 diagnosed early-stage breast cancer (stages I and II) as 
 reported to the Surveillance, Epidemiology, and End 
Results (SEER) registries of Georgia and Los Angeles 
County, California, from 2013 to 2015 (n = 5080; a 
70% response rate).
Women who participated in the iCanCare study 
were asked to identify via survey their attending 
physicians, including their PCPs. Participants identified 
2946 unique PCPs. PCPs were considered to be ineli-
gible if they were of a different specialty, were unable 
to be  located, were retired, or were deceased (n = 150). 
A stratified sample of eligible PCPs were then surveyed 
about their experiences in caring for patients with breast 
cancer. High-volume PCPs (identified by more than 
1 patient in the iCanCare study; n = 618) were first 
selected for inclusion, and then a 10% random sample 
of low-volume PCPs (identified by only 1 patient in 
iCanCare; n = 234) were selected for inclusion. Survey 
packets contained the PCP survey, a $40 incentive, a 
study brochure, an introductory letter, a prestamped 
return envelope, and informed consent information 
(physicians were not required to sign and return it with the 
completed survey). To encourage responses, we provided 
a $40 cash  incentive and again used a modified Dillman 
approach by including reminders to nonrespondents. 
Of the 852 eligible PCPs who were mailed surveys, 518 
completed them, and this resulted in a 60.8% response 
rate. Included in this analysis were 517 PCPs who were 
linked to 1077 eligible patients in the iCanCare patient 
sample. This study was approved by the University of 
Michigan  institutional review board and the state and 
institution institutional review boards of the SEER 
registries.
Measures
Questionnaire content was developed on the basis of 
our prior work,12,16 a literature review, and a conceptual 
framework hypothesizing that PCP involvement leads to 
improved primary care quality. We used standard tech-
niques to assess content validity, including a systematic 
review by design experts, cognitive pretesting with clini-
cians, and pilot studies in selected clinician populations.
PCP-reported level of involvement in treatment 
decision making
We ascertained the PCP-reported level of involvement 
in treatment decision making by asking the respondent 
PCPs how often they discussed 1) which type of surgery 
a patient should have, 2) whether or not a patient should 
have radiation therapy, and 3) whether or not a patient 
should have chemotherapy. Response categories included 
never to always (on a 5-point Likert-type scale), and they 
were categorized into more involvement (sometimes, 
often, or always) or less involvement (rarely or never) for 
each of the 3 treatment modalities (surgery, radiation, 
and chemotherapy).
PCP-reported ability to participate in treatment 
decision making
We then ascertained PCPs’ ability to participate in 
 treatment decision making by asking respondent PCPs 
how comfortable they were in discussing specific breast 
cancer treatments (surgery, radiation, and chemotherapy), 
with the response options ranging from not at all com-
fortable to extremely comfortable (on 5-point Likert-type 
scales). We also asked participants whether they had the 
knowledge necessary to participate in treatment decision 
making and whether they were confident in their ability 
to help patients with treatment-related decision making, 
with the response options for both ranging from strongly 
disagree to strongly agree on 5-point Likert-type scales. An 
overall score of PCPs’ ability to participate was then created 
with the mean responses to the 3 items, with higher scores 
reflecting a more positive appraisal for each specific treat-
ment decision (surgery, radiation, and chemotherapy).
PCP-reported characteristics
The PCP-reported covariates in this analysis included 
 demographic and practice factors. Demographic char- 
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acteristics collected via survey included the age at sur-
vey (in 10-year increments), sex (male or female), and 
race (white, black, Hispanic, Asian, or other/unknown). 
Practice characteristics included the specialty (general/ 
internal medicine, family medicine, obstetrics/gynecol-
ogy, or other), breast cancer volume (patients per year), 
and practice type (physician practice vs other practice 
type).
Statistical Analyses
We first evaluated the overall proportion of PCPs who 
 reported being more involved versus less involved in 
surgical, radiation, and chemotherapy decisions among 
the  respondent PCPs. The bivariate associations of 
 PCP-reported characteristics with PCP-reported involve-
ment in surgery, radiation, and chemotherapy decisions 
were then evaluated in the PCP sample with 2-sided 
t tests and chi-square tests where appropriate. The 
 bivariate  associations between PCP-reported scores of 
their ability to participate in treatment decision making 
and PCP-reported involvement in surgical, radiation, 
and chemotherapy decisions were examined with 2-sided 
t tests. Multivariate logistic regression was then used to 
characterize the association between the PCP-reported 
ability to participate in treatment decision making and 
PCP involvement in the 3 treatment decisions with 3 sep-
arate models, which were adjusted for age, race, patients 
with breast cancer per year, practice type, and SEER site. 
All multivariate analyses incorporated weights to account 
for differential probabilities of survey responses across 
characteristics of these PCPs.
Using the linked PCP-patient data set (517 PCPs 
linked to 1077 patients), we then explored whether the 
PCP-reported level of involvement in the 3 treatment 
decisions was associated with patient reports of PCP 
involvement in their treatment decisions. All analy-
ses were performed with SAS 9.4 (SAS Institute, Cary, 
North Carolina), and P < .05 was considered statistically 
significant.
RESULTS
Overall, 34% of the respondent PCPs reported more 
involvement (somewhat, often, or always) in surgi-
cal treatment decisions of their patients with breast 
cancer rather than less involvement (never or rarely). 
Approximately one-quarter reported more involvement 
in radiation decisions (23%) and chemotherapy deci-
sions (22%; Fig. 1).
Table 1 displays the distribution of more PCP 
involvement in surgery, radiation, and chemotherapy 
decisions by levels of PCP-reported demographic and 
practice characteristics. The median age at survey was 
greater among PCPs who reported more involvement 
in the treatment decisions across all 3 treatment types 
(all P values <.01). PCP-reported race was significantly 
associated with PCP-reported involvement in surgery 
and radiation decisions, with nonwhite PCPs compos-
ing a greater proportion of those who reported more 
involvement versus less involvement in surgery (39.6% 
vs 32.7%; P < .01), radiation (45.1% vs 32.3%; P = 02), 
and chemotherapy decisions (44.3% vs 32.7%; P = .03). 
PCPs in private practice (vs other practice types) com-
posed a greater proportion of those who reported more 
involvement in surgery (75.0% vs 63.8%; P = .01), 
radiation (78.0 vs 64.5%; P < .01), and chemotherapy 
decisions (75.5% vs 64.3%; P = .05) in comparison with 
those who reported less involvement in these decisions. 
A higher breast cancer volume was also significantly 
associated with more PCP involvement in radiation and 
chemotherapy decisions (both P values = .02). Medical 
specialty and PCP sex were not found to be associated 
with the extent of PCP involvement in any of the 3 treat-
ment decisions (Table 1).
Figure 1. Distributions of PCP-reported involvement (more 
vs less) in surgery, radiation, and chemotherapy decisions 
(n = 517). PCP-reported involvement was defined as more 
involvement (sometimes, often, or always) or less involvement 
(rarely or never) for each of the 3 treatment modalities 
(surgery, radiation, and chemotherapy). Respondents were 
asked how often they discussed the following: 1) which 
type of surgery a patient should have, 2) whether or not a 
patient should have radiation therapy, and 3) whether or not 
a patient should have chemotherapy. Response categories 
ranged from never to always (on a 5-point Likert-type scale). 
PCP indicates primary care provider.
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Figure 2. Mean PCP ability-to-participate scores (along with 95% confidence intervals) for surgery, radiation, and chemotherapy 
decisions by levels of PCP-reported involvement in each decision. All P values for associations between the PCP-reported ability-
to-participate scores and the PCP-reported involvement in treatment decisions were <.001. PCP indicates primary care provider.
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TABLE 1. Distributions of PCP-Reported Characteristics by PCP-Reported Involvement in Breast Cancer 
Surgery, Radiation, and Chemotherapy Treatment Decisions (n = 517)
PCP Characteristic
Surgery Decision Radiation Decision Chemotherapy Decision
Less 
Involvement
More 
Involvement P
Less 
Involvement
More 
Involvement P
Less 
Involvement
More 
Involvement P
PCP age, mean (SE), y 52.7 (0.5) 55.9 (0.8) <.01 53.0 (0.5) 56.6 (1.0) <.01 53.1 (0.5) 56.2 (1.0) <.01
PCP sex, No. (%) .19 .85 .54
Male 181 (57.3) 83 (50.9) 205 (55.3) 58 (54.2) 203 (54.3) 60 (57.7)
Female 135 (42.7) 80 (49.1) 166 (44.7) 49 (45.8) 171 (45.7) 44 (42.3)
PCP race/ethnicity,  
No. (%)
.14 .02 .03
White 202 (67.3) 93 (60.4) 239 (67.7) 56 (54.9) 241 (67.3) 54 (55.7)
Nonwhite 98 (32.7) 61 (39.6) 114 (32.3) 46 (45.1) 117 (32.7) 43 (44.3)
Breast cancer volume, 
No. (%)
.08 .02 .02
≤10/y 280 (89.5) 134 (83.8) 330 (89.4) 84 (80.8) 335 (89.3) 79 (80.6)
≥11/y 33 (10.5) 26 (16.2) 39 (10.6) 20 (19.2) 40 (10.7) 19 (19.4)
Practice type, No. (%) .01 <.01 .05
Physician practice 203 (63.8) 123 (75.0) 240 (64.5) 85 (78.0) 245 (64.3) 80 (75.5)
Other practice type 115 (36.2) 41 (25.0) 132 (35.5) 24 (22.0) 130 (34.7) 26 (24.5)
Specialty, No. (%) .51 .14 .36
General/internal 
medicine
148 (46.7) 79 (47.9) 168 (45.2) 58 (53.2) 170 (45.3) 56 (52.8)
Family medicine 142 (44.8) 66 (40.0) 170 (45.7) 38 (34.9) 169 (45.1) 39 (36.8)
Obstetrics/
gynecology
17 (5.4) 14 (8.5) 24 (6.4) 7 (6.4) 25 (6.7) 6 (5.7)
Other 10 (3.2) 6 (3.6) 10 (2.7) 6 (5.5) 11 (2.9) 5 (4.7)
Site, No. (%) <.01 .32 .34
Georgia 197 (59.9) 77 (46.1) 218 (56.6) (51.4) 220 (56.6) 55 (51.4)
California 132 (40.1) 90 (53.9) 167 (43.4) (48.6) 169 (43.4) 52 (48.6)
Abbreviations: PCP, primary care provider; SE, standard error.
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Figure 2 displays the mean scores for the 
PCP-reported ability to participate in decision making 
across levels of PCP-reported involvement in each of the 
3 treatment decisions. The PCP-reported ability to par-
ticipate was positively associated with the level of partic-
ipation in all 3 treatment decisions. PCPs with higher 
mean ability-to-participate scores were more likely to 
 report more involvement (vs less involvement) in surgical 
decisions (mean, 3.6 vs 2.3), radiation decisions (mean, 
3.8 vs 2.3), and chemotherapy decisions (mean, 3.7 vs 
2.3; all P values < .001).
We also assessed the distribution of the  individual 
components of the PCP-reported ability-to- participate 
scores among those who reported that they were 
involved in the treatment decisions. Of the 34% of PCPs 
who reported more involvement in surgery decisions, 22% 
reported that they were not comfortable having these 
discussions, and 17% reported that they did not have the 
necessary knowledge to participate in treatment decision 
making. Of the 23% who reported more  involvement 
in radiation decisions, 16% reported that they were 
not comfortable having these discussions, and 14% 
reported that they lacked the confidence to help with these 
decisions. Similar gaps in comfort, knowledge, and con-
fidence were seen among those who reported that they 
were more involved in chemotherapy decisions also 
(Fig. 3).
Figure 4 displays the multivariate-adjusted 
associations between the PCP-reported ability to par-
ticipate in treatment decision making and their level of 
involvement in surgery, radiation, and chemotherapy 
decisions. The odds of PCPs reporting more involve-
ment in surgical treatment decisions increased more than 
6-fold for each unit increase in their ability-to-participate 
scores (odds ratio [OR], 6.01; 95% confidence interval 
[CI], 4.16-8.68; Fig. 4). Similar statistically significant 
and positive associations were seen for the radiation and 
chemotherapy decisions (OR for radiation, 8.37; 95% 
CI, 5.16-13.58; OR for chemotherapy, 6.56; 95% CI, 
4.23-10.17; Fig. 4). PCP age was positively associated 
with more PCP-reported involvement in surgery and 
radiation decisions (OR for surgery, 1.41; 95% CI, 
1.04-1.91; OR for radiation, 1.58; 95% CI, 1.09-2.28) 
but not chemotherapy decisions (OR, 1.38; 95% CI, 
0.98-1.95; Fig. 4).
We also examined the validity of PCPs’ reports 
of their participation in the treatment decisions by 
comparing them with patients’ reports of their PCPs’ 
participation in their breast cancer treatment decisions 
(517 PCPs linked to 1077 patients). There was a clear 
pattern of concordance for all 3 decisions, which are 
displayed in Supporting Table 1. PCPs’ reporting 
of their participation in surgery and radiation deci-
sions was concordant with patients’ reporting of the 
PCPs’ involvement in their treatment decisions (both 
P values < .01).
Figure 3. Distributions of the components of the PCPs’ 
ability-to-participate scores among PCPs who reported that 
they were more involved in treatment decisions: (A) surgery 
decisions (n = 167), (B) radiation decisions (n = 107), and (C) 
chemotherapy decisions (n = 111). PCP indicates primary care 
provider.
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DISCUSSION
Our findings from this sample of PCPs who treat women 
with early-stage breast cancer in general practice settings 
suggest that up to a third of PCPs report that they are 
involved in multimodal breast cancer treatment deci-
sions, including surgical, radiation, and chemotherapy 
decisions. In addition, older PCPs and those who more 
positively appraise their ability to participate in these 
decisions are more likely to be involved in these deci-
sions. However, little variation is seen in PCP-reported 
involvement in these decisions across PCP-reported prac-
tice factors. To our knowledge, this is one of the first 
studies to assess the extent to which PCPs are involved in 
these complex treatment decisions and to examine factors 
associated with their level of involvement.
Our results suggest that up to a third of PCPs 
participate in breast cancer surgery decisions, but they 
participate less often in radiation and chemotherapy 
decisions. Prior literature suggests that PCPs may be 
increasingly called upon to engage in cancer treatment 
decision making.12,13 Our prior work with the iCanCare 
study patient participants found that more than one-
third of women reported that their PCP was involved in 
their breast cancer treatment decisions, and this partici-
pation was greatest among minority women, those with 
less education, and those with more comorbidities.12 In 
addition, prior research suggests that more than one-
third of men with prostate cancer report that their PCP 
helped them with their treatment decision.13 Our find-
ings expand upon this prior work by investigating PCPs’ 
reports of involvement in different cancer treatment 
decisions. As initial treatment options for early-stage 
breast cancer increasingly become more nuanced, PCPs 
may be more often consulted by their patients for 
their input. As such, efforts to educate PCPs about the 
specifics of the various treatment options so that they can 
effectively support patients in making high-quality deci-
sions appear warranted.
Our findings also suggest that PCP involvement in 
these treatment decisions is more common among PCPs 
who positively appraise their ability to participate in 
these decisions. Although the majority of PCPs in this 
sample positively appraised their ability to participate 
in these decisions, a notable minority of PCPs reported 
gaps in their ability to participate despite also reporting 
that they were involved in these treatment decisions. This 
included PCPs who reported that they were not comfort-
able with participating in these decisions, did not have 
the knowledge necessary to do so, and were less confi-
dent in their ability to help with these decisions. We also 
assessed whether PCPs’ appraisal of their ability to par-
ticipate varied across patient demographic characteristics 
such as age, race, education, and insurance status, and we 
found very little variation (data not shown). Thus, our 
findings highlight that opportunities exist to improve 
PCPs’ knowledge about breast cancer treatment options 
as well as their confidence in their ability to participate in 
cancer treatment decision making more broadly.
Because PCPs are typically the providers that  manage 
patients’ other comorbidities and general medical care, 
they often have more established relationships with their 
 patients. As a result, they may be more attuned to the pref-
erences and values of their patients than cancer specialists 
whom patients have only recently met.17 Yet, discussions 
about how to best support PCPs’ involvement in team-
based cancer care often focus on their involvement after 
the initial treatment process is complete, and they often do 
not encompass their involvement both before and during 
Figure 4. Multivariate-adjusted odds ratios and 95% confidence intervals estimating the odds of more PCP involvement in 
surgery, radiation, and chemotherapy treatment decisions. BrCa indicates breast cancer; LA, Los Angeles; OB/GYN, obstetrics/
gynecology; PCP indicates primary care provider.
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treatment. A growing body of evidence supports the idea 
that PCPs want to be involved in the care of patients with 
cancer throughout the continuum.18-21 If PCPs are engaged 
during the active-treatment phase already, involving them 
in initial treatment decisions may provide an additional 
opportunity for shared decision making.
Our prior work suggests that engaging other 
individuals who provide decision support and using 
online communication tools during the breast cancer 
decision process lead to more deliberative treatment deci-
sions.1,2 It is, therefore, plausible that additional provider 
engagement in the decision-making process may lead 
to a more deliberative and preference-sensitive decision. 
However, prior research suggests that receiving help from 
a PCP did not influence treatment patterns in men with 
localized prostate cancer.13 Therefore, the extent to which 
PCP involvement in the treatment decision may influ-
ence a patient’s appraisal of the decision-making process 
and the ultimate treatment decision itself remains poorly 
understood.
This study has a number of strengths, including the 
sampling of primary care physicians who care for patients 
with breast cancer, a high response rate for a primary care 
survey, and the validation of PCP reports of engagement 
against patient experiences. However, there are limita-
tions that merit comment. First, we do not have a direct 
measure of clinician involvement in decision making. 
However, we did find that clinician and patient reports 
were concordant. Second, the study was cross-sectional, 
so our ability to make inferences about the temporality 
of these associations is limited. Third, we do not have 
information on the content of these conversations, nor 
do we know whether the patient or PCP initiated them. 
Fourth, because this was an observational study, we are 
unable to account for unmeasured confounders. Finally, 
our population included PCPs in Los Angeles County, 
California, and Georgia; thus, generalizability to other 
populations may be limited.
In conclusion, up to one-third of PCPs report 
participating in multimodal breast cancer treatment 
 decisions. Yet, gaps exist in PCPs’ self-reported knowledge 
about these treatment options and in their confidence in 
their ability to help patients with these decisions. Efforts 
to better incorporate and communicate with PCPs and to 
educate them about the specifics of cancer treatments may 
be warranted to promote collaborative cancer care.
FUNDING SUPPORT
This work was funded by grant P01CA163233 from the National Cancer 
Institute to the University of Michigan and by a research grant from 
the University of Michigan Rogel Cancer Center. Lauren P. Wallner’s 
time was also supported by grant K07 CA201052 from the National 
Cancer Institute. Cancer incidence data collection was supported by 
the California Department of Public Health pursuant to California 
Health and Safety Code Section 103885; by the Centers for Disease 
Control and Prevention’s National Program of Cancer Registries 
under cooperative agreement 5NU58DP003862-04/DP003862; 
and by the National Cancer Institute’s Surveillance, Epidemiology, 
and End Results Program under contract HHSN261201000140C 
awarded to the Cancer Prevention Institute of California, under con-
tract HHSN261201000035C awarded to the University of Southern 
California, and under contract HHSN261201000034C awarded 
to the Public Health Institute. Cancer incidence data collection in 
Georgia was supported by the National Cancer Institute under con-
tract HHSN261201300015I (task order HHSN26100006) and by the 
Centers for Disease Control and Prevention under cooperative agree-
ment 5NU58DP003875-04-00. The ideas and opinions  expressed 
herein are those of the authors. The State of California, the Department 
of Public Health, the National Cancer Institute, and the Centers for 
Disease Control and Prevention and their contractors and subcontrac-
tors had no role in the design or conduct of the study; in the collection, 
management, analysis, or interpretation of the data; or in the prepara-
tion, review, or approval of the manuscript.
CONFLICT OF INTEREST DISCLOSURES
Allison W. Kurian reports a research grant to her institution from Myriad 
Genetics outside the submitted work. Reshma Jagsi reports grants from 
the National Institutes of Health, the Doris Duke Charitable Foundation, 
the Komen Foundation, and the Greenwall Foundation; personal fees 
from Vizient and Amgen for consulting; and stock options from Equity 
Quotient outside the submitted work. The other authors made no 
disclosures.
AUTHOR CONTRIBUTIONS
Lauren P. Wallner: Conceptualization (including questionnaire design), 
methods, data collection, data analyses, and writing and editing of the 
original and final manuscripts. Yun Li: Statistical and formal data analy-
ses and visualization. M. Chandler McLeod: Statistical and formal data 
analyses and visualization. Joan Gargaro: Analysis, administration, visuali-
zation, and editing. Allison W. Kurian: Methods and review and editing. 
Reshma Jagsi: Methods and review and editing. Archana Radhakrishnan: 
Methods and review and editing. Ann S. Hamilton: Data collection and 
methods. Kevin C. Ward: Data collection and methods. Sarah T. Hawley: 
Conceptualization, methods, review and editing, funding, and supervision. 
Steven J. Katz: Conceptualization, methods, review and editing, funding, 
and supervision.
REFERENCES
 1. Wallner LP, Li Y, McLeod MC, et al. Decision-support 
networks of women newly diagnosed with breast cancer. Cancer. 
2017;123:3895-3903.
 2. Wallner LP, Martinez KA, Li Y, et al. Use of online communication 
by patients with newly diagnosed breast cancer during the treatment 
decision process. JAMA Oncol. 2016;2:1654-1656.
 3. Maly RC, Umezawa Y, Ratliff CT, Leake B. Racial/ethnic group 
differences in treatment decision-making and treatment received 
among older breast carcinoma patients. Cancer. 2006;106:957-965.
 4. Maly RC, Umezawa Y, Leake B, Silliman RA. Determinants of 
participation in treatment decision-making by older breast cancer 
patients. Breast Cancer Res Treat. 2004;85:201-209.
 5. Hawley ST, Griggs JJ, Hamilton AS, et al. Decision involvement and 
receipt of mastectomy among racially and ethnically diverse breast 
cancer patients. J Natl Cancer Inst. 2009;101:1337-1347.
 6. Stiggelbout AM, Jansen SJ, Otten W, Baas-Thijssen MC, van Slooten 
H, van de Velde CJ. How important is the opinion of significant 
others to cancer patients’ adjuvant chemotherapy decision-making? 
Support Care Cancer. 2007;15:319-325.
Original Article
1822 Cancer  June 1, 2019
 7. Ohlen J, Balneaves LG, Bottorff JL, Brazier AS. The influence of 
significant others in complementary and alternative medicine 
decisions by cancer patients. Soc Sci Med. 2006;63:1625-1636.
 8. Gilbar R, Gilbar O. The medical decision-making process and 
the family: the case of breast cancer patients and their husbands. 
Bioethics. 2009;23:183-192.
 9. American Cancer Society. Breast Cancer Facts & Figures 2016-2017. 
Atlanta, GA: American Cancer Society; 2017.
 10. Levit LA, Balogh EP, Nass SJ, Ganz PA, eds. Delivering High-
Quality Cancer Care: Charting a New Course for a System in Crisis. 
Washington, DC: National Academies Press; 2013.
 11. Cohen HJ. A model for the shared care of elderly patients with cancer. 
J Am Geriatr Soc. 2009;57(suppl 2):S300-S302.
 12. Wallner LP, Abrahamse P, Uppal JK, et al. Involvement of primary 
care physicians in the decision making and care of patients with 
breast cancer. J Clin Oncol. 2016;34:3969-3975.
 13. Radhakrishnan A, Grande D, Ross M, et al. When primary care 
providers (PCPs) help patients choose prostate cancer treatment. 
J Am Board Fam Med. 2017;30:298-307.
 14. Hawley ST, Janz NK, Griffith KA, et al. Recurrence risk perception 
and quality of life following treatment of breast cancer. Breast Cancer 
Res Treat. 2017;161:557-565.
 15. Jagsi R, Abrahamse PH, Lee KL, et al. Treatment decisions and 
employment of breast cancer patients: results of a population-based 
survey. Cancer. 2017;123:4791-4799.
 16. Wallner LP, Li Y, Furgal AKC, et al. Patient preferences for primary 
care provider roles in breast cancer survivorship care. J Clin Oncol. 
2017;35:2942-2948.
 17. Roorda C, de Bock GH, Scholing C, et al. Patients’ preferences for 
post-treatment breast cancer follow-up in primary care vs. secondary 
care: a qualitative study. Health Expect. 2015;18:2192-2201.
 18. Del Giudice ME, Grunfeld E, Harvey BJ, Piliotis E, Verma S. 
Primary care physicians’ views of routine follow-up care of cancer 
survivors. J Clin Oncol. 2009;27:3338-3345.
 19. Lawrence RA, McLoone JK, Wakefield CE, Cohn RJ. Primary care 
physicians’ perspectives of their role in cancer care: a systematic 
review. J Gen Intern Med. 2016;31:1222-1236.
 20. Potosky AL, Han PK, Rowland J, et al. Differences between pri-
mary care physicians’ and oncologists’ knowledge, attitudes and 
practices regarding the care of cancer survivors. J Gen Intern Med. 
2011;26:1403-1410.
 21. Smith SL, Wai ES, Alexander C, Singh-Carlson S. Caring for 
survivors of breast cancer: perspective of the primary care physician. 
Curr Oncol. 2011;18:e218-e226.
